![](/cdn/assets/images/search/clock.png)
We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Synairgen Plc | LSE:SNG | London | Ordinary Share | GB00B0381Z20 | ORD 1P |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
0.155 | 3.43% | 4.675 | 4.35 | 5.00 | - | 25,623 | 16:35:16 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
Pharmaceutical Preparations | 0 | -17.65M | -0.0876 | -0.52 | 9.1M |
Date | Subject | Author | Discuss |
---|---|---|---|
23/4/2020 09:49 | That’s amazing news if true Likya. | ![]() talk2dubya | |
23/4/2020 09:46 | From lse board... Bristol patient with an underlying condition. On his death bed, but said he is now not using his nebuliser. After 4 days he said that the symptoms left as soon ad they arrived. Was on BBC1 at 9:30. His name was Lee Peters | ![]() likya123 | |
23/4/2020 09:39 | Ticking down to fill another large buy me thinks . | ![]() imjustdandy | |
23/4/2020 09:36 | So that's two very big buys in the last 30mins, hmm that kind of money you would have to be very very confident. Balls of steel! | slinkyj | |
23/4/2020 09:32 | 104k buy at full ask...leaky ship? | ![]() likya123 | |
23/4/2020 09:23 | Excellent news on recruitment - thanks for sharing! | ![]() pdt | |
23/4/2020 09:21 | Here we go.... just needs to break 61 today | slinkyj | |
23/4/2020 09:21 | Hope so Slinky. more PR would be good. I have emailed The Guardian asking why more isn't being made of this , what could be, massive step forward by an English company in battling Covid 19 and future virus pandemics | ![]() peachie 74 | |
23/4/2020 09:17 | Not surprised, I'm all in. I would put that kind of extra money in if I could at this price. This is going up no doubt. | slinkyj | |
23/4/2020 09:14 | £62,000 buy just gone through - someone must feel confident | ![]() imjustdandy | |
23/4/2020 09:13 | General market a little bit wobbly today. Lots of unknowns circulating. I think the buys willsoon come flooding over here, it's one of the the most positive and biggest reward stocks right now. A progress RNS would be fab right now. I always say communication is key in business. | slinkyj | |
23/4/2020 08:54 | Added a few today. With a vaccine 18 months off, anything that eases the severity of COVID, especially something that can be self administered..... | ![]() waterloo01 | |
23/4/2020 08:53 | Been fast tracked under "urgent" category by NHIR since initial time frame was proposed by Synairgen. From Birmingham news looks like all patients recruited so we've indeed been very much fast tracked! Results will be much earlier too and within next couple of weeks and possibly sooner as time is very much of the essence in this unprecednted situation. I believe we'll be above a quid in days and onto many pounds shortly after. This mornings activity mirroring yesterdays so far meaning we are in for another very blue day! | ![]() likya123 | |
23/4/2020 08:47 | As confirmed to me by the company, results expected to be published around early June. | ![]() aquilla | |
23/4/2020 08:38 | Thanks. So we're looking at June for results? | ![]() dovey21 | |
23/4/2020 08:36 | They can't unblind the trial until the last patient has completed it. | ![]() d1nga | |
23/4/2020 08:29 | Good morning all. I've lost track a little..was the trial expected to be 6 or 8 weeks? When do members here expect news on initial dosing results?... The patient recruitment has been staggered; I wondered if they would wait to complete the whole trial of all patients before releasing news. | ![]() dovey21 | |
23/4/2020 08:12 | Another hospital in Manchester also took first patient last week. hxxps://research.cmf | ![]() crookie3634 | |
23/4/2020 08:03 | Not completely surprised as we were put into "urgent" category by NHIR. What was most interesting is this happened just after a fortnight of first patient being dosed so it only increases my already high confidence levels that results will be clinically statistically positive. | ![]() likya123 | |
23/4/2020 07:55 | I doubt that any one centre would have a particular target. Usually recruitment just carries on in all centres until the total number is reached. So it looks like recruitment probably has completed, which is somewhat amazing! | ![]() nobbygnome | |
23/4/2020 07:49 | Probably voted down by someone who got the wrong end of the stick. This end of the disease is a different matter. SNG001 hopefully stops people getting to this point, lessoning the effective of the wave that starts in the lungs following advancement of the infection, cytokine storm etc leading to lung cell damage. The latter end of disease may well be helped by blood thinning agents. lets stop them getting there first ! Great find re Birmingham trial | ![]() peachie 74 | |
23/4/2020 07:41 | I know just look at 88e lol | ![]() tialouise | |
23/4/2020 07:39 | I’m rather surprised that someone voted down Pro’s post on micro vascular thrombosis (pulmonary, coronary arteries, renal and elsewhere). The medical community has been aware for some time that this is most often the cause of sudden deterioration and death. Low molecular weight heparins are recommended along with cytokines storm/ARDS management with, for example, antiIL6 and cautious immune suppression. Prior to this I feel that INFbeta is likely to be a safe and effective intervention to prevent these severe and potentially lethal complications. | ![]() freedosh | |
23/4/2020 07:38 | Going to fly today.. From lse board.. ’’SG016, which looked at the effectiveness of a drug, SNG001, in improving lung function for patients with COVID-19, was able to finish recruitment within a week. Initial results from all trials are expected within weeks’’ | ![]() likya123 |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions